LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 20.1% in November

LAVA Therapeutics (NASDAQ:LVTX) saw a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 21,100 shares, a drop of 20.1% from the November 15th total of 26,400 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 61,100 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On LAVA Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Pathway Financial Advisors LLC increased its position in shares of LAVA Therapeutics by 70.8% during the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after buying an additional 42,500 shares during the period. XTX Topco Ltd purchased a new position in shares of LAVA Therapeutics during the 2nd quarter worth approximately $55,000. Finally, Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics during the third quarter valued at approximately $32,000.

Analyst Ratings Changes

A number of research firms have weighed in on LVTX. JMP Securities reaffirmed a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research note on Thursday. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, LAVA Therapeutics presently has an average rating of “Hold” and an average price target of $4.67.

LAVA Therapeutics Stock Performance

LVTX traded down $0.09 on Friday, hitting $1.11. 157,486 shares of the company were exchanged, compared to its average volume of 528,124. The stock has a market capitalization of $28.14 million, a PE ratio of -1.08 and a beta of 0.43. LAVA Therapeutics has a 12 month low of $1.08 and a 12 month high of $6.47. The firm has a fifty day simple moving average of $1.69 and a two-hundred day simple moving average of $1.83.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.